Here's the good news:GLP-1does not blockautophagy. The real driver of this process is ketone production, which kicks in when your body enters nutritionalketosis(burning fat for fuel).
Abstract The biology ofautophagyinhealth and disease conditions has been intensively analyzed for decades. Several potential interventions can induceautophagyinpreclinical research; however, none of these interventions are ready for translation to clinical practice yet. The topic of the current review is the molecular regulation ofautophagyby glucagon, glucagon-like peptide (GLP)-1and...
Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship betweenGLP-1mimetics and ketogenesis.
Semaglutide is a medication that is part of a group of drugs calledGLP-1receptor agonists. These drugs are designed to mimic the actions of a natural hormone in the body called glucagon-like peptide-1 (GLP-1). This hormone plays a key role in regulating blood sugar, controlling appetite, and managing body weight. Let's explore how semaglutide works in the body, why it is used, and how it ...
Inthis study, we define the role and mechanisms of one of the most popularGLP-1RA agonists, Semaglutide, in ADPKD. We show that the expression ofGLP-1R is decreased in Pkd1 mutant renal epithelial cells and kidneys.Treatmentwith Semaglutide delays cyst growth in aggressive and long-lasting Pkd1 mutant mouse models.
